AICAR
Acadesine / AICA Ribonucleotide / ZMP
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide, also known as Acadesine) is a synthetic analog of adenosine monophosphate that directly activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. Originally developed as a cardioprotective agent for use during cardiac surgery, it gained notoriety as an "exercise mimetic" capable of triggering metabolic adaptations typically associated with endurance training. AICAR is banned by the World Anti-Doping Agency (WADA) and is classified as a metabolic modulator on the prohibited substances list.
Mécanisme d'action
AMP-kinase activator that mimics the metabolic effects of exercise. Increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through direct AMPK phosphorylation. Shifts cellular metabolism toward an endurance-trained state.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Research protocols use 150-500mg daily via subcutaneous injection. Animal studies used 500mg/kg. Often cycled 4-8 weeks. Sometimes combined with GW501516 in research settings.
Notes de recherche
Clinical Research Status
AICAR underwent Phase III clinical trials for reduction of ischemic injury during coronary artery bypass graft surgery, though it ultimately did not receive FDA approval for this indication. Research interest shifted dramatically after 2008 Salk Institute studies demonstrated that AICAR administration alone could improve running endurance in sedentary mice by 44%. It remains an investigational compound with no approved medical indications, though academic research into AMPK activation continues across metabolic disease, cancer, and aging fields.
Key Published Findings
The landmark Narkar et al. (2008) paper in Cell demonstrated that AICAR treatment for 4 weeks reprogrammed muscle metabolism toward oxidative fiber types and enhanced running endurance without exercise training. AMPK activation by AICAR increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through PGC-1alpha signaling pathways. In cardiac ischemia studies, AICAR reduced post-surgical complications including atrial fibrillation and the need for inotropic support.
Safety Profile
Clinical trial data from cardiac surgery studies showed AICAR to be relatively well-tolerated at therapeutic doses, with hypoglycemia and lactic acidosis being the primary dose-limiting concerns. Renal toxicity has been observed at higher doses due to uric acid accumulation from purine metabolism. Long-term safety data in healthy populations is essentially nonexistent, as most human data comes from short-term perioperative use in cardiac patients.
Comparison to Related Compounds
Unlike GW501516 (Cardarine), which activates PPAR-delta downstream of AMPK, AICAR directly activates AMPK itself, affecting a broader range of metabolic pathways including autophagy and mTOR suppression. SLU-PP-332 represents a newer generation of exercise mimetics targeting estrogen-related receptors rather than AMPK. Metformin also activates AMPK but through indirect mitochondrial complex I inhibition rather than direct allosteric activation, resulting in a different pharmacological profile.
Community Observations
Users report enhanced endurance and fat oxidation, though the effects are considered modest compared to expectations set by animal studies. The high cost per effective dose and requirement for injection limit its practical use in performance enhancement contexts. Some users combine AICAR with GW501516 based on the original Salk Institute research showing synergistic effects, though this combination carries compounded safety unknowns.
Moitié de vie
~2-3 hours
Réconstitution
Bacteriostatic water (BAC) or sterile saline
Conservation
Lyophilisé
Refrigerate 2-8C up to 12 months.
Réconstitué
Refrigerate 2-8C. Use within 14 days.
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que AICAR ?
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide, also known as Acadesine) is a synthetic analog of adenosine monophosphate that directly activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. Originally developed as a cardioprotective agent for use during cardiac surgery, it gained notoriety as an "exercise mimetic" capable of triggering metabolic adaptations typically associated with endurance training. AICAR is banned by the World Anti-Doping Agency (WADA) and is classified as a metabolic modulator on the prohibited substances list.
Comment agit AICAR ?
AMP-kinase activator that mimics the metabolic effects of exercise. Increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis through direct AMPK phosphorylation. Shifts cellular metabolism toward an endurance-trained state.
Quel est le statut réglementaire de AICAR aux États-Unis ?
Research chemical (not FDA-approved)
Quelle est la demi-vie de AICAR ?
~2-3 hours
Sous quels autres noms AICAR est-il connu ?
Acadesine, AICA Ribonucleotide, ZMP
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète